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Unrelated cord blood transplantation (UCBT) provides a curative therapy for patients with hematological
malignancies. The effect of HLA mismatches in UCBT is currently the subject of debate. HLA-mismatched
UCBT may lead to improved leukemia control but also to graft-versus-host disease (GVHD), resulting in
nonrelapse mortality (NRM). The aim of this study was to investigate whether indirect recognition of mis-
matched HLA provides an explanation for the graft-versus-tumor effect and risk of GVHD. The probability of
indirect recognition was predicted by the Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) model.
The effect of the numbers of PIRCHE presented on HLA class I and II (PIRCHE-I and -II) was studied in 134
pediatric patients. To study the effects of higher numbers of PIRCHE, patients were divided in 2 equally sized
groups, using the median number of PIRCHE as cutoff values. Proportional hazard models and competing risk
analyses were performed to study the effect of PIRCHE on the clinical outcomes relapse, acute and chronic
GVHD, NRM, and disease-free and overall survival. Above median PIRCHE-I were associated with reduced
relapse risk (HR, .26; 95% CI, .07 to .94; P ¼ .04), evaluating the 50 patients transplanted for a malignancy. Both
PIRCHE-I and -II were not associated with other clinical outcomes, including GVHD and NRM. These data
suggest that high PIRCHE-I may lead to improved graft-versus-tumor effects after UCBT, without an
accompanying GVHD risk. Inclusion of PIRCHE in UCB selection criteria may enhance UCBT outcome, which
needs to be tested in prospective studies.
 2016 American Society for Blood and Marrow Transplantation.INTRODUCTION
Unrelated cord blood transplantation (UCBT) provides an
attractive alternative for patients in need of allogeneic he-
matopoietic cell transplantation (HCT) but lacking an HLA-
matched sibling donor. HLA mismatches are well tolerated
in cases of UCBT, and an acceptable UCB donor is available for
virtually every patient [1].edgments on page 173.
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y for Blood andMarrow Transplantation.Whether HLA mismatches in UCBT are favorable or
detrimental is the subject of ongoing debate. On one hand,
HLA mismatches may enhance the graft-versus-tumor (GVT)
effect, leading to signiﬁcantly reduced relapse risks after
HLA-mismatched UCBT [2-6]. On the other hand, HLA-
mismatched UCBT has been associated with an increased
risk of graft-versus-host disease (GVHD), resulting in non-
relapse mortality (NRM) [5,7]. Dissection of the GVT poten-
tial of HLA mismatches from the GVHD risk would greatly
enhance UCBT outcome.
Indirect T cell recognition of HLA mismatches is a po-
tential explanation for both the GVT effect and GVHD. During
indirect recognition donor T cells recognize peptides derived
from the mismatched HLA that are presented on shared HLA
[8]. The Predicted Indirectly ReCognizable HLA Epitopes
(PIRCHE) algorithm provides a method to distinguish HLA
Table 1
Baseline Characteristics
Variable Overall Malignancies
Median age at transplantation,
yr (range)
4.93 (.14-22.74) 9.81 (1.29-19.08)
Median WBC infused, 107/kg
(range)
6.05 (.59-33.20) 6.28 (1.69-23.50)
Patient sex
Female 54 (40.3) 17 (34.0)
Male 80 (59.7) 33 (66.0)
Diagnosis
Malignancy* 50 (37.3) 50 (100.0)
Inborn error of metabolism 35 (26.1)
Immune deﬁciency 33 (24.6)
Bone marrow failure 13 (9.7)
Other 3 (2.2)
Conditioning regimeny
TBI/VP16 11 (8.2) 11 (22.0)
BuCy(MeL) 30 (22.4) 6 (12.0)
FluBu(Clo) 79 (59.0) 29 (58.0)
CyFlu 12 (9.0) 3 (6.0)
Treo-based 2 (1.5) 1 (2.0)
Match grade
10/10 25 (18.7) 6 (12.0)
9/10 30 (22.4) 11 (22.0)
8/10 28 (20.9) 11 (22.0)
7/10 22 (16.4) 9 (18.0)
6/10 12 (9.0) 6 (12.0)
5/10 17 (12.7) 7 (14.0)
TBI indicates total body irradiation; VP16, etoposide; Bu, busulfan; Cy,
cyclophosphamide; MeL, melphalan; Flu, ﬂudarabine; Clo, clofarabin; Treo,
treosulfan.
Values are total number of cases with percents in parentheses, unless
otherwise noted.
* Of the malignancies, most were myeloid (n ¼ 23, 46%).
y BuCy(MeL) was used for patients transplanted before 2009, FluBu(Clo)
after 2009.
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indirect T cell recognition [9-11]. The algorithm predicts with
computational methods which peptides derived from the
mismatched HLA alleles can be presented by donorepatient
shared HLA. It thereby generates the opportunity of scoring
the immunogenic level of each donorepatient HLA
combination. PIRCHE can be presented by HLA class I and II
(PIRCHE-I and -II), which theoretically correlates to the
probability of CD8þ and CD4þ T cell recognition, respectively.
In adult unrelated donor HCT with peripheral bloodederived
stem cells, both PIRCHE-I and -II were correlated to GVHD
development [10,11]. Thus, PIRCHE seem to provide the op-
portunity of dissecting HLA mismatches into those with high
and low alloreactive CD8þ and CD4þ T cell potential.
We hypothesized that the GVT potential and the GVHD
risk of HLA mismatches in UCBT are correlated to the
numbers of PIRCHE-I and/or -II and that, consequently, PIR-
CHE may provide a prognostic tool that ultimately improves
clinical outcome. To address this issue all pediatric patients
who received a UCBT at the University Medical Center
Utrecht were studied for the correlation of PIRCHE-I and -II
with clinical outcomes.
METHODS
Patients
Clinical data were collected prospectively. Patients had given written
consent in accordance with the Declaration of Helsinki. HLA typing was
retrospectively performed for all patient and donor pairs for HLA-A, -B, -C,
-DRB1, and -DQB1. HLA typing was performed by PCR (whole gene ampli-
ﬁcation for HLA class I and exon 2 to 4 ampliﬁcation for HLA class II) and
sequencing, using the SBTexcellerator HLA-A, -B, -C, -DRB1, and -DQB1 kits,
following the recommendations of the manufacturer (GenDx, Utrecht, The
Netherlands). Puriﬁed sequencing products were electrophoresed using a
3730 DNA-Analyzer (Applied Biosystems, Foster City, CA), and sequences
were analyzed using the SBTengine software (GenDx). All ambiguities at the
second ﬁeld level were resolved using sequence-speciﬁc primers (GenDx). If
required, additional exons were ampliﬁed and sequenced for HLA class II.
This typing approach led to unambiguous amino acid sequences for all pa-
tients and donors. Inclusion criteriawere availability of complete HLA typing
and, in case of multiple-donor HCT (double-unit UCBT or UCBT combined
with haploidentical donor cells), established engraftment of 1 of 2 donors.
Transplantation procedures of the University Medical Center Utrecht were
described previously [12].
In total, 156 patients received UCBT from 2004 until 2014, of which 134
met the inclusion criteria. The median age was 5 years (range, 0 to 23).
Patients were transplanted for various underlying diseases, withmalignancy
as the main indication. Median follow-up was 1 year (range, 0 to 11).
Detailed clinical characteristics are listed in Table 1.
PIRCHE
PIRCHE were determined as described previously [10,11]. In short,
PIRCHE-I were identiﬁed in 2 steps. First, proteasome-mediated cleavage
and transportation via the TAP (transporter associated with antigen pro-
cessing) channel were predicted for all donor and patient HLA molecules
using NetChop C-term 3.0 (http://www.cbs.dtu.dk/services/). Subsequently,
peptides were tested for their binding capacity to the HLA-A, -B, and -C
molecules that were shared between the donor and patient, using
NetMHCpan 2.4 (http://www.cbs.dtu.dk/services/). Only peptides with IC50
binding values 500 nM were accepted as relevant binders. For PIRCHE-II,
the nonameric binding cores of potential 15-meric HLA-DRB1 binders
were predicted with NetMHCIIPan 2.0 (http://www.cbs.dtu.dk/services/),
considering IC50 binding values 1000 nM as relevant. Only unique patient-
derived peptideeHLA complexes were classiﬁed as PIRCHE. The PIRCHE
prediction algorithm is accessible via www.pirche.org. GVH-directed
PIRCHE were determined for multiple-donor HCT based on the engrafting
donor: dominant UCB in case of double UCB (differing dominance in 2 and
therefore excluded from the analyses) and UCB in case of haplo-UCBT.
Statistical Analysis
Data were retrospectively analyzed. Differences in groups of PIRCHE
were assessed by chi-square test for categorical variables and with Student’s
t-test for continuous variables. The clinical endpoints studied were relapse,
acute and chronic GVHD, NRM, disease-free survival (DFS), and overallsurvival (OS). For the endpoints related to the GVT effect (relapse and DFS),
only patients with a malignancy were studied. The impact of other end-
points was studied in the entire cohort, because all these patients were at
risk. The effects of PIRCHE and other donor-, patient- and transplantation-
associated variables on the time-dependent clinical outcomes were
analyzed using proportional hazard models for chronic GVHD, DFS, and OS.
Competing risk analyses were performed for relapse, acute GVHD, and
NRM. Graft failure and NRM were considered competing risks for relapse;
graft failure, relapse, and NRM were considered competing risks for acute
GVHD; and relapse and graft failure were considered competing risks for
NRM. To study the effect of higher numbers of PIRCHE, patients were divided
into 2 groups using the median as a cutoff value.
Statistical models evaluated the following parameters for inclusion in
the multivariate models: patient age, patient sex, conditioning regimen,
serotherapy, patient cytomegalovirus serostatus, primary disease, prior HCT,
the number of CD34þ and WBCs infused/kg, and prior acute GVHD in the
model for chronic GVHD. Factors associated with outcome in univariate
analyses (P < .10) were included in multivariate models.
Statistical procedures were performed with SPSS version 20.0 (SPSS Inc.,
Chicago, IL), and competing risk analyses were performed in R version 3.0.0
(R Foundation for Statistical Computing, Vienna, Austria). P < .05 were
considered statistically signiﬁcant.RESULTS
The median numbers of PIRCHE were 3.5 for PIRCHE-I
(range, 0 to 40) and 13 for PIRCHE-II (range, 0 to 96). The
average numbers and standard deviations of PIRCHE-I and -II
derived from each locus are indicated in Supplementary
Table 1. To study a potential dose-dependent effect of PIR-
CHE, patients were divided into 2 equally sized groups,
guided by the median PIRCHE numbers. Patients in the high
PIRCHE-I (4 or more) had bone marrow failure signiﬁcantly
more often as indication for the HCT (P¼ .02), and patients in
the low PIRCHE-I group (0 to 3) were signiﬁcantly more often
male (P ¼ .01); other baseline characteristics did not
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differing factors were not associated with the tested clinical
endpoints, and therefore the uneven distribution has likely
not impacted the analyses.
We hypothesized that a higher number of PIRCHE in-
creases the likelihood of T cell recognition and thus enhances
the GVT effect. To study the effect of PIRCHE on GVT reac-
tivity, the relapse incidences of 2 groups of PIRCHE were
compared in the 50 patients transplanted for a malignancy.
The effect on relapse was analyzed in univariate and multi-
variate competing risk analyses, regarding NRM and graft
failure as competing risks. Overall, the 5-year relapse inci-
dence was 22%, which was signiﬁcantly lower in the group of
patients that presented 4 or more PIRCHE-I (11%, P ¼ .04;
hazard ratio [HR], .26; 95% conﬁdence interval [CI], .07 to .94;
P ¼ .04) (Figure 1, Table 2). PIRCHE-II (0 to 12 versus 13 or
more) were not signiﬁcantly associated with relapse. Thus, 4
or more PIRCHE-I were associated with a reduced relapse
risk, suggesting that donor CD8þ T cells recognize patient
tumor cells, thereby substantiating the well-established
crucial role of alloreactive CD8þ T cells in tumor control
[13,14].
The positive GVT effect of PIRCHE might clinically be
counterbalanced by an increased GVHD risk. We therefore
studied the effect of PIRCHE on acute and chronic GVHD in
the total study group. Neither PIRCHE-I nor PIRCHE-II were
signiﬁcantly associated with (severe) acute or chronic GVHD
development (Table 2). In addition, PIRCHE-I and -II were not
signiﬁcantly associated with NRM and OS (Table 2).
Because PIRCHE-I have a positive antitumor effect, we
studied whether patients with high PIRCHE-I have improved
DFS rates. In patients with a malignancy, there was a trend
for patients having an increased probability of DFS when
they presented 4 or more PIRCHE-I compared with the 0 to 3
PIRCHE-I group (HR, .41; 95% CI, .15 to 1.13; P ¼ .09) (Table 2,
Figure 1).
DISCUSSION
In this unique, single-center pediatric patient cohort,
PIRCHE-I values above 3 were signiﬁcantly associated with a
reduced relapse rate. High PIRCHE-I and -II did not result in
detrimental (side) effects, as reﬂected by similar GVHD andFigure 1. The probability of relapse (A) and DFS (B) by PIRCHE-I groups. Patients with
in a trend for improved DFS.NRM. These results therefore suggest that selection of UCB
units with high numbers of PIRCHE-I may improve trans-
plant outcome for patients with a malignant disease.
The GVT potential of PIRCHE-I may explain why HLA
mismatches in UCBT can be associated with a reduced
relapse risk [2-6]. The association between PIRCHE-I and
relapse suggests that PIRCHE-speciﬁc CD8þ T cells may be
involved in antitumor responses. In vitro studies
regarding PIRCHE-speciﬁc T cells of patients after UCBT
may allow elucidating why in some UCBT settings the
alloreactivity of HLA mismatches is directed toward the
positive antitumor response, resulting in improved sur-
vival [6], whereas in others it results in GVHD and the
detrimental NRM [5,7]. The current data suggest that in
our local center especially tumor-reactive PIRCHE-speciﬁc
T cells can be identiﬁed.
This proof-of-principle study included a limited number
of patients with a malignancy (N¼ 50). Before PIRCHE can be
implemented in the donor-selection procedure, validation
studies are warranted to investigate whether the GVT po-
tential of PIRCHE-I does result in better survival and whether
the effect of PIRCHE-I may be speciﬁcally related to, for
example, myeloid malignancies, because the GVT effect of
donor lymphocyte infusions is mostly restricted to myeloid
leukemias [15]. These aspects need to be addressed in larger
cohorts, with a speciﬁc focus on patients transplanted for
acute leukemia.
Theoretically, increasing numbers of PIRCHE-I increase
the probability to develop tumor-speciﬁc CD8þ T cells. The
absolute number of PIRCHE-I was, however, not associated
with relapse in competing risk analyses (HR, .99; 95% CI, .89
to 1.11; P ¼ .87) or DFS (HR, .99; 95% CI, .92 to 1.06; P ¼ .77).
Evidently, these analyses were hampered by the small cohort
size (Supplementary Figure 1). Moreover, the lack of such a
correlation may be explained by a nonlinear association be-
tween PIRCHE and the GVT effect, which likely reaches a
plateau phase at high numbers of PIRCHE-I. Finally, some
PIRCHE-I may be more immunogenic than others (ie, more
often to result in T cell responses). Therefore, in line with the
observed data, we currently propose that the cutoff of 3
PIRCHE-I is a theoretical threshold above which clinical T cell
responses are to be expected.4 or more PIRCHE-I had a signiﬁcantly reduced probability of relapse, resulting
Table 2
Effect of PIRCHE-I and -II in Multivariate Models
Outcome PIRCHE-I PIRCHE-II
HR 95% CI P HR 95% CI P
Relapse (n ¼ 50) .26 .07-.94 .04 .45 .13-1.60 .21
Acute GVHD
Grades II-IV .72 .35-1.46 .36 .95 .47-1.93 .88
Grades III-IV 1.11 .38-3.28 .84 .02 .82-11.07 .10
Severe chronic GVHD
(n ¼ 114)
2.20 .36-13.25 .39 3.94 .44-35.36 .22
DFS (n ¼ 50) .41 .15-1.13 .09 .89 .33-2.39 .81
NRM 1.65 .76-3.57 .21 1.01 .47-2.17 .97
OS 1.09 .59-2.02 .77 .86 .47-1.58 .63
Number of evaluated patients was 134 unless otherwise indicated. Multi-
variate models included cytomegalovirus status; acute GVHD grades II-IV;
prior HCT; and prior HCT, number of CD34þ cells infused, number of WBC
infused.
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associated with antitumor speciﬁcity. The PIRCHE-I
FQILVMLEM derived from either HLA-DQB1*03:01 or
-DQB1*06:01 was presented by 5 patients who did not
develop relapse and by none of the patients who did
relapse (P ¼ .10). This ﬁnding suggests that epitopes
derived from HLA-DQB1 presented to CD8þ T cells can
result in tumor-speciﬁc responses. Potentially, these HLA-
DQB1ederived PIRCHE-I have higher expression levels on
leukemic cells than on patient tissue, because they are HLA
class II derived. This higher expression level may direct the
GVT response. Future studies need to be conducted to
conﬁrm the association of this epitope with GVT responses,
both epidemiologically and in vitro.
There was no signiﬁcant effect of PIRCHE on acute and
chronic GVHD observed. Nonetheless, the HRs for the 13
or more PIRCHE-II group compared with the 0 to 12
PIRCHE-II group for severe acute and chronic GVHD were
high. Potentially, the lack of a signiﬁcant correlation for
PIRCHE-II with GVHD is the result of the low GVHD
incidence after UCBT combined with the relatively small
sample size of this cohort. Thus, larger cohorts are also
warranted to further investigate the correlation of PIRCHE-
II with GVHD development. Based on the current data,
when implementing PIRCHE in the donor-selection
criteria, one may avoid CB donors recognizing 13 or
more PIRCHE-II, thereby potentially preventing severe
acute and chronic GVHD.
PIRCHE may introduce a new level of matching for UCBT.
PIRCHE can be predicted for all patientedonor combinations
when high-resolution HLA typing of the donor and patient
are available. PIRCHE predictions could be used to assist in
the selection procedure when the match grade and cell dose
of multiple CB units are considered acceptable, as an extra
criterion. Ultimately, PIRCHE may provide an opportunity to
select HLA-mismatched CB donors with a high antitumor
potential by selecting CB donors that recognize 4 or more
PIRCHE-I.
In conclusion, this study provides data on a potential
novel donor selection method. We have demonstrated that
high PIRCHE-I values enhance the GVT potential of HLA-
mismatched UCBT without increasing the risk of GVHD and
NRM. The results from our local proof-of-principle study
require external validation in either retrospective or pro-
spective studies.ACKNOWLEDGMENTS
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